BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35027481)

  • 1. Targeting Protein Arginine Methyltransferase 5 Suppresses Radiation-induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation.
    Owens JL; Beketova E; Liu S; Shen Q; Pawar JS; Asberry AM; Yang J; Deng X; Elzey BD; Ratliff TL; Cheng L; Choo R; Citrin DE; Polascik TJ; Wang B; Huang J; Li C; Wan J; Hu CD
    Mol Cancer Ther; 2022 Mar; 21(3):448-459. PubMed ID: 35027481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JNJ-64619178 radiosensitizes and suppresses fractionated ionizing radiation-induced neuroendocrine differentiation (NED) in prostate cancer.
    Pawar JS; Al-Amin MY; Hu CD
    Front Oncol; 2023; 13():1126482. PubMed ID: 36959798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting CREB inhibits radiation-induced neuroendocrine differentiation and increases radiation-induced cell death in prostate cancer cells.
    Suarez CD; Deng X; Hu CD
    Am J Cancer Res; 2014; 4(6):850-61. PubMed ID: 25520873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer.
    Beketova E; Fang S; Owens JL; Liu S; Chen X; Zhang Q; Asberry AM; Deng X; Malola J; Huang J; Li C; Pili R; Elzey BD; Ratliff TL; Wan J; Hu CD
    Cancer Res; 2020 Nov; 80(22):4904-4917. PubMed ID: 32999000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRMT5 promotes chemotherapy-induced neuroendocrine differentiation in NSCLC.
    Shen Q; Liu Y; Deng X; Hu CD
    Thorac Cancer; 2023 Jun; 14(18):1764-1773. PubMed ID: 37140020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
    Deng X; Shao G; Zhang HT; Li C; Zhang D; Cheng L; Elzey BD; Pili R; Ratliff TL; Huang J; Hu CD
    Oncogene; 2017 Mar; 36(9):1223-1231. PubMed ID: 27546619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients.
    Deng X; Elzey BD; Poulson JM; Morrison WB; Ko SC; Hahn NM; Ratliff TL; Hu CD
    Am J Cancer Res; 2011; 1(7):834-44. PubMed ID: 22016831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AMPK/SIRT1 signaling through p38MAPK mediates Interleukin-6 induced neuroendocrine differentiation of LNCaP prostate cancer cells.
    Natani S; Dhople VM; Parveen A; Sruthi KK; Khilar P; Bhukya S; Ummanni R
    Biochim Biophys Acta Mol Cell Res; 2021 Sep; 1868(10):119085. PubMed ID: 34171447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer.
    Enriquez C; Cancila V; Ferri R; Sulsenti R; Fischetti I; Milani M; Ostano P; Gregnanin I; Mello-Grand M; Berrino E; Bregni M; Renne G; Tripodo C; Colombo MP; Jachetti E
    Cancer Res; 2021 Aug; 81(16):4257-4274. PubMed ID: 34185677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reprogramming landscape highlighted by dynamic transcriptomes in therapy-induced neuroendocrine differentiation.
    Asberry AM; Liu S; Nam HS; Deng X; Wan J; Hu CD
    Comput Struct Biotechnol J; 2022; 20():5873-5885. PubMed ID: 36382181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylosome Protein 50 and PKCδ/p38δ Protein Signaling Control Keratinocyte Proliferation via Opposing Effects on p21Cip1 Gene Expression.
    Saha K; Eckert RL
    J Biol Chem; 2015 May; 290(21):13521-30. PubMed ID: 25851901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulforaphane inhibits PRMT5 and MEP50 function to suppress the mesothelioma cancer cell phenotype.
    Ezeka G; Adhikary G; Kandasamy S; Friedberg JS; Eckert RL
    Mol Carcinog; 2021 Jul; 60(7):429-439. PubMed ID: 33872411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure.
    Hu CD; Choo R; Huang J
    Front Oncol; 2015; 5():90. PubMed ID: 25927031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel GRK3-HDAC2 regulatory pathway is a key direct link between neuroendocrine differentiation and angiogenesis in prostate cancer progression.
    Naderinezhad S; Zhang G; Wang Z; Zheng D; Hulsurkar M; Bakhoum M; Su N; Yang H; Shen T; Li W
    Cancer Lett; 2023 Sep; 571():216333. PubMed ID: 37543278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
    Liu B; Li L; Yang G; Geng C; Luo Y; Wu W; Manyam GC; Korentzelos D; Park S; Tang Z; Wu C; Dong Z; Sigouros M; Sboner A; Beltran H; Chen Y; Corn PG; Tetzlaff MT; Troncoso P; Broom B; Thompson TC
    Clin Cancer Res; 2019 Nov; 25(22):6839-6851. PubMed ID: 31439587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulforaphane suppresses PRMT5/MEP50 function in epidermal squamous cell carcinoma leading to reduced tumor formation.
    Saha K; Fisher ML; Adhikary G; Grun D; Eckert RL
    Carcinogenesis; 2017 Aug; 38(8):827-836. PubMed ID: 28854561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and Biological Characterization of PRMT5:MEP50 Protein-Protein Interaction Inhibitors.
    Asberry AM; Cai X; Deng X; Santiago U; Liu S; Sims HS; Liang W; Xu X; Wan J; Jiang W; Camacho CJ; Dai M; Hu CD
    J Med Chem; 2022 Oct; 65(20):13793-13812. PubMed ID: 36206451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy pathway is required for IL-6 induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cells.
    Chang PC; Wang TY; Chang YT; Chu CY; Lee CL; Hsu HW; Zhou TA; Wu Z; Kim RH; Desai SJ; Liu S; Kung HJ
    PLoS One; 2014; 9(2):e88556. PubMed ID: 24551118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells.
    Sang M; Hulsurkar M; Zhang X; Song H; Zheng D; Zhang Y; Li M; Xu J; Zhang S; Ittmann M; Li W
    Oncotarget; 2016 Jul; 7(29):45171-45185. PubMed ID: 27191986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRMT5: a putative oncogene and therapeutic target in prostate cancer.
    Beketova E; Owens JL; Asberry AM; Hu CD
    Cancer Gene Ther; 2022 Mar; 29(3-4):264-276. PubMed ID: 33854218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.